Quidel (NASDAQ:QDEL) Stock Crosses Above 50 Day Moving Average of $57.35
Quidel Co. (NASDAQ:QDEL)’s share price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $57.35 and traded as high as $58.11. Quidel shares last traded at $57.74, with a volume of 999 shares changing hands.
Several equities analysts have recently weighed in on QDEL shares. ValuEngine lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Monday, July 8th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Zacks Investment Research upgraded shares of HAYS PLC/ADR from a “sell” rating to a “hold” rating in a research report on Tuesday, June 18th. Raymond James restated an “average” rating and set a $23.00 price objective on shares of in a research report on Monday, April 15th. Finally, Canaccord Genuity restated a “speculative buy” rating and set a GBX 70 ($0.91) price objective on shares of Bacanora Lithium in a research report on Monday, July 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $71.17.
The company has a fifty day moving average price of $57.48. The stock has a market cap of $2.26 billion, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 0.84 and a beta of 1.36. The company has a quick ratio of 0.91, a current ratio of 1.33 and a debt-to-equity ratio of 0.25.
In other Quidel news, Director Charles P. Slacik sold 1,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $55.19, for a total value of $55,190.00. Following the completion of the transaction, the director now directly owns 8,703 shares in the company, valued at $480,318.57. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kenneth F. Buechler sold 2,002 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $60.58, for a total transaction of $121,281.16. Following the completion of the transaction, the director now owns 49,771 shares of the company’s stock, valued at $3,015,127.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,963 shares of company stock valued at $4,018,580. Corporate insiders own 14.10% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. United Services Automobile Association boosted its holdings in shares of Quidel by 7.7% during the fourth quarter. United Services Automobile Association now owns 7,914 shares of the company’s stock worth $386,000 after purchasing an additional 566 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Quidel by 7.6% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,375 shares of the company’s stock worth $745,000 after purchasing an additional 800 shares during the period. Legal & General Group Plc boosted its holdings in shares of Quidel by 6.9% during the fourth quarter. Legal & General Group Plc now owns 13,708 shares of the company’s stock worth $670,000 after purchasing an additional 883 shares during the period. NumerixS Investment Technologies Inc boosted its holdings in shares of Quidel by 178.3% during the first quarter. NumerixS Investment Technologies Inc now owns 1,400 shares of the company’s stock worth $90,000 after purchasing an additional 897 shares during the period. Finally, Strs Ohio acquired a new stake in shares of Quidel during the first quarter worth approximately $58,000. Institutional investors own 91.41% of the company’s stock.
Quidel Company Profile (NASDAQ:QDEL)
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Featured Article: Market Capitalization
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.